*ST赛隆：注射用尼可地尔获得药品注册证书

Core Viewpoint - *ST Sailong (002898) announced that its wholly-owned subsidiary, Hunan Sailong Pharmaceutical (Changsha) Co., Ltd., has recently received the drug registration certificate for injectable Nicorandil from the National Medical Products Administration, which is used for the treatment of unstable angina pectoris [1] Group 1 - The approval of injectable Nicorandil represents a significant milestone for the company in expanding its product portfolio [1] - Injectable Nicorandil is specifically indicated for the treatment of unstable angina pectoris, addressing a critical medical need in the cardiovascular sector [1]